Veracyte has been building genomic diagnostics since 2008, starting with a test for thyroid cancer that could tell doctors whether a suspicious nodule was benign — potentially avoiding unnecessary surgery. That product, the Afirma test, became widely adopted and established Veracyte as a leader in genomic diagnostics.
Since then, the company has expanded into lung cancer, bladder cancer, breast cancer, and kidney disease. Each test analyzes tissue or blood samples at the molecular level using machine learning algorithms trained on large genomic datasets. The goal is always the same: give doctors more precise information so they can avoid unnecessary procedures or choose the right therapy sooner.
Veracyte went public in 2013 and has made several acquisitions to broaden its diagnostic portfolio. The company acquired HalioDx in 2021, gaining access to immune profiling technology used in colorectal and other cancers. Veracyte processes tests in its own CLIA-certified labs and works directly with pathologists and oncologists. Annual revenue exceeds $400 million, and the company continues investing in new tests that turn complex genomic data into clear, actionable clinical answers.
